225 related articles for article (PubMed ID: 16061679)
1. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
3. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
Yang CH; Chen YC; Kuo ML
Anticancer Res; 2003; 23(3B):2519-23. PubMed ID: 12894535
[TBL] [Abstract][Full Text] [Related]
4. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
5. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
10. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
11. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
[TBL] [Abstract][Full Text] [Related]
12. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Tsai CM; Chiu CH; Chang KT; Chen JT; Lai CL; Chen YM; Hsiao SY
J Thorac Oncol; 2012 Aug; 7(8):1218-27. PubMed ID: 22659964
[TBL] [Abstract][Full Text] [Related]
16. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Carcaboso AM; Elmeliegy MA; Shen J; Juel SJ; Zhang ZM; Calabrese C; Tracey L; Waters CM; Stewart CF
Cancer Res; 2010 Jun; 70(11):4499-508. PubMed ID: 20460504
[TBL] [Abstract][Full Text] [Related]
18. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
19. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
[TBL] [Abstract][Full Text] [Related]
20. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Chauvier D; Morjani H; Manfait M
Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
